Clinical Trials
323
Active:251
Completed:51
Trial Phases
5 Phases
Phase 1:147
Phase 2:17
Phase 3:17
+2 more phases
Drug Approvals
40
CIMA_AEMPS:16
EMA:10
SFDA:8
+1 more agencies
Drug Approvals
Vinorelbine Tartrate Soft Capsule
- Product Name
- 酒石酸长春瑞滨软胶囊
- Approval Number
- 国药准字HJ20140658
- Approval Date
- Dec 26, 2023
NMPA
Vinorelbine Tartrate Soft Capsule
- Product Name
- 酒石酸长春瑞滨软胶囊
- Approval Number
- 国药准字HJ20140657
- Approval Date
- Dec 20, 2023
NMPA
Vinorelbine Tartrate Injection
- Product Name
- 诺维本
- Approval Number
- 国药准字HJ20140084
- Approval Date
- Jun 7, 2023
NMPA
Vinorelbine Tartrate Injection
- Product Name
- 诺维本
- Approval Number
- 国药准字HJ20140083
- Approval Date
- Jun 7, 2023
NMPA
Vinorelbine Tartrate Soft Capsule
- Product Name
- 酒石酸长春瑞滨软胶囊
- Approval Number
- H20140658
- Approval Date
- May 7, 2019
NMPA
Vinorelbine Tartrate Soft Capsule
- Product Name
- 酒石酸长春瑞滨软胶囊
- Approval Number
- H20140657
- Approval Date
- May 7, 2019
NMPA
Clinical Trials
Distribution across different clinical trial phases (191 trials with phase data)• Click on a phase to view related trials
Phase 1
147 (77.0%)Phase 2
17 (8.9%)Phase 3
17 (8.9%)Not Applicable
6 (3.1%)Phase 4
4 (2.1%)Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational International Study
Active, not recruiting
- Conditions
- X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 27
- Registration Number
- NCT07096206
- Locations
- 🇫🇷
Necker hospital, Paris, France
🇩🇪Uniklinikum Erlangen, Erlangen, Germany
An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)
Recruiting
- Conditions
- Early Breast CancerSkin ConditionQuality of Life
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 156
- Registration Number
- NCT06690489
- Locations
- 🇫🇷
Institut du Cancer de Montpellier - Val d'Aurelle, Montpellier, France
🇬🇷Sygros Hospital, Athens, Greece
🇬🇷Aristotle University of Thessaloniki, Thessaloníki, Greece
The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study.
Terminated
- Conditions
- Sore-throatCough
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 12
- Registration Number
- NCT06688370
- Locations
- 🇫🇷
Cen Experimental, Dijon, France
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 140
- Registration Number
- NCT06669117
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Gabrail Cancer Research Center, Canton, Ohio, United States
🇺🇸Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States
Study on Structum® in Adult Patients With Osteoarthritis (TRUST)
Completed
- Conditions
- Osteoarthritis, Knee
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 151
- Registration Number
- NCT06623773
- Locations
- 🇵🇱
Maciej Dołżyński, Bialystok, Poland
🇵🇱Piotr Ligocki, Bydgoszcz, Poland
🇵🇱Elżbieta Pietrus- Dunaszewska, Katowice, Poland
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
No news found